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Devices in Heart Failure
Patients—Who Benefits From ICD
and CRT?
Alexander Breitenstein* and Jan Steffel
Electrophysiology, Department of Cardiology, University Hospital Zurich, Zurich, Switzerland
Despite advances in heart failure treatment, this condition remains a relevant medical
issue and is associated with a high morbidity and mortality. The cause of death
in patients suffering from heart failure is not only a result of hemodynamic failure,
but can also be due to ventricular arrhythmias. Implantable cardioverter defibrillators
(ICDs) are these days the only tool to significantly reduce arrhythmic sudden death;
but not all patients benefit to the same extend. In addition, cardiac resynchronization
therapy (CRT) is another tool which is used in patients suffering from heart fialure.
Even though both devices have been investigated in large randomized trials, both ICD
and CRT remain underutilized in many countries. This brief review focuses on various
aspects in this regard including a short overview on upcoming device novelties in the
near future.
Keywords: heart failure, cardiac resynchronization, implantable cardioverter defibrillator, subcutaneous ICD
(S-ICD), imaging
INTRODUCTION
According to current ESC guidelines, heart failure can be separated into heart failure
with preserved ejection fraction (LVEF > 50%; HFpEF), mid-range EF (LVEF 40–49%;
HFmrEF) and reduced ejection fraction (LVEF < 40%; HFrHF) (1). The cause of death
in patients suffering from heart failure is not only a result of hemodynamic failure but
also suddenly and unexpectedly occurring from ventricular electrical disturbances such
as ventricular tachycardia and -fibrillation. Implantable cardioverter defibrillators (ICDs)
represent the only available tool in our treatment armamentarium proven to prevent
arrhythmic sudden cardiac death. In addition, cardiac resynchronization therapy (CRT)
is an established treatment option significantly improving both quality of life as well
as mortality.
In spite of these proven benefits, both ICD as well as CRT therapy remain
underutilized in many countries (2). The reasons are manifold. This brief review
focusses on some of the most important aspects in this regard, including continuing
medical education regarding the pathophysiology, epidemiology, clinical trial results as
well as novel technologies, which are paramount to allow for optimal dissemination
of these important therapies and to reduce morbidity and mortality in this fragile
patient population.
Breitenstein and Steffel Devices in Heart Failure
IMPLANTABLE CARDIOVERTER
DEFIBRILLATOR (ICD) THERAPY IN
PATIENTS SUFFERING FROM CHRONIC
HEART FAILURE (CHF)—OF PRIMARY AND
SECONDARY PREVENTION, IN ISCHEMIC
AND NON-ISCHEMIC CARDIOMYOPATHY
Patients with heart failure and reduced ejection fraction (LVEF
< 35%) are at an increased risk of sudden cardiac death due to
ventricular arrhythmias. This risk is highest in those who already
suffered from previous ventricular arrhythmic events (3). In this
“secondary prevention” situation where no reversible cause such
as an acute myocardial infarction can be identified, an ICD is
recommended with a class IA indication (if survival> 1 year with
good functional status is predicted) according to ESC guidelines
(1) (Table 1).
The situation is more complex in primary prevention. Even
though current guidelines recommend the implantation of an
ICD in patients suffering from heart failure with an LVEF≤ 35%
despite at least 3 months of optimal medical treatment, a NYHA
class II-IVa and a predicted survival of > 1 year, there seems to
be a discrepancy of the beneficial effect of an ICD depending
on the underlying heart disease. Indeed, patients with ischemic
heart disease have a class IA indication, while in the non-ischemic
population the indication level is IB (Table 1). Two large trials
investigated the role of an ICD in the primary prevention context:
The Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)
(4) and the Multicenter Automatic Defibrillator Implantation
TABLE 1 | Current ICD and CRT indications according to the ESC guidelines.
Indication ICD Class
Secondary
prevention
• In patients with documented VF or
haemodynamically not tolerated VT
• Absence of reversible causes or within 48h
after myocardial infarction
• Reasonable expectation of survival with a
good functional status > 1 year
IA
Primary
prevention
Severely impaired LV function (≤ 35 %)
• With NYHA II-IVa
• Despite optimal medical treatment for ≥ 3
months
• Ischemic cardiomyopathy
Non-ischemic cardiomyopathy
IA
IB
Indication CRT Class
• Severely impaired LV function (≤ 35 %)
• NYHA II-IVa
• Despite optimal medical treatment for ≥ 3
months
• With LBBB and QRS duration > 150ms
With LBBB and QRS duration 130-149ms
IA
IB
• With non-LBBB and QRS duration > 150ms
With non-LBBB and QRS duration
130-149 ms
IIA
IIB
Trial II (MADIT-II) (5). Both trials demonstrated a mortality
benefit in patients with severely reduced LVEF (≤ 30% in the
MADIT-II trial, ≤ 35% in SCD-HeFT). In MADIT-II, which
enrolled patients with ischemic heart disease and a previous
myocardial infarction, the ICD offered a relative mortality
reduction of 31% over 5 years. SCD-HeFT on the other hand
recruited a mixed population of ischemic and non-ischemic
cardiomyopathy. Subgroup analyses did not show a difference
in the outcome of total mortality reduction between ischemic
and non-ischemic heart disease indicating a similar effect in
both patient population. In contrast, themore recent randomized
Danish Study to Assess the Efficacy of ICDs in Patients with
Non-ischemic Systolic Heart Failure on Mortality (DANISH)
trial investigated the role of primary prevention ICDs exclusively
in non-ischemic cardiomyopathy; it demonstrated a significant
reduction in sudden cardiac death in patients with non-ischemic
heart disease with an LVEF ≤ 35%—but without an effect on
all-cause mortality, the predefined primary endpoint (6).
How do these results fit together? Do we need to rethink
the indication for primary prevention ICD implantation in the
entire non-ischemic population? Even though a recent survey
of the European Heart Rhythm Association (EHRA) has shown
that already 4 months after the publication of the DANISH
trial, nearly 50% of physicians changed their current practice
in recommending an ICD implantation in a non-ischemic
cardiomyopathy patient (7), a meta-analysis has shown a benefit
of primary prevention ICDs even regarding total mortality (8).
What to do in light of these controversial data? Rather than
jumping to conclusions and withholding an ICD on a general
basis in this population, it may be worthwhile to take a look
at the data in a little bit more detail. Indeed, improving patient
selection in non-ischemic heart disease may be the way to go to
maximize the benefit of ICD therapy. Subgroup analyses of the
DANISH trial have shown that younger patients with an age of
< 70 years or those with less severe heart failure (as indicated
by lower NT-proBNP levels) indeed demonstrated a reduction
in all-cause mortality (6, 9). These data imply that using just the
LVEF alone to predict whether an individual patient will more
likely die from pump failure vs. ventricular arrhythmias (10–12)
may be insufficient. On a more general level, these results further
indicate that our current way of risk-stratification is insufficient
and that amore refined way of looking at things is warranted. The
Seattle Heart Failure Model, for example, incorporates various
risk factors including age as well as laboratory parameters to
predict mortality in heart failure patients, and may represent
an attractive model for patient selection for an ICD. Another
promising strategy is to assess the potential proarrhythmogenic
myocardial substrate. Late gadolinium enhancement (LGE) on
cardiac MRI corresponds to areas of myocardial fibrosis (13),
and reports have shown that patients with LGE exert a higher
risk for sudden cardiac death and ventricular arrhythmias (14).
Especially mid-wall LGE was associated with a substantial nine-
fold increase in the rate of sudden cardiac death/aborted sudden
cardiac death in patients with dilated cardiomyopathy and a
LVEF ≥ 40% (15). In addition to CMRI, electroanatomical
mapping (EAM) is a currently widespread way of invasively
investigating myocardial scaring (Figure 1). By measuring local
Frontiers in Cardiovascular Medicine | www.frontiersin.org 2 August 2019 | Volume 6 | Article 111
Breitenstein and Steffel Devices in Heart Failure
FIGURE 1 | Electroanatomical voltage mapping of the left ventricle (posterior view). Red areas indicate scar tissue, whereas pink areas demonstrate healthy
myocardium.
electrical properties in the context of an electrophysiological
study, areas of scar tissue can be differentiated from healthy
myocardium (16). Even though both imaging modalities display
great promise, their value needs to be prospectively tested in
randomized trials. In addition to imaging modalities, various
other markers of increased arrhythmia risk can potentially be
incorporated in the ICD decision making process such as genetic
testing, circulating biomarkers, non-invasive electrophysiological
testing etc.
On the other hand, it needs to be kept in mind that
the reduction in sudden cardiac death from an ICD in this
population not translating into a total-mortality benefit may not
only be because of an excess in non-arrhythmogenic deaths—it
may also be due to complications and morbidity of the device
itself. Therefore, further investigations and developments in
improving device technology are essential. The subcutaneous
implantable cardioverter defibrillator (S-ICD) represents a novel
model of an ICD designed to reduce the occurrence as well
as the associated morbidity (and mortality) of one of the most
relevant lifetime risks of transvenous device systems: infection.
The generator in a S-ICD is located at the left lateral chest
in the space between the anterior serratus and the latissimus
dorsi muscles. The lead is tunneled within the subcutaneous
tissue toward the xiphoid process and from advanced alongside
the sternum cranially (Figure 2). Large randomized trials are
on its way, but registries are very promising with lower lead
complications and a higher lead survival over time in the SICD
population (17). As such, recent ESC guidelines recommend a
subcutaneous ICD with a class IIa indication as an alternative
to transvenous ICDs in the absence of contraindication (18). A
subcutaneous defibrillator is not suitable if patients are in need
for bradycardia pacing or cardiac resynchronization as well as
overdrive pacing; however, the solution of most these problems,
however, appears to be only a matter of time, since a combination
of the S-ICD with a leadless pacemaker will enter into clinical
trials in the near future. Furthermore, patients need to undergo
a pre-procedure sensing vector screening to ensure adequate
sensing of the QRS complex and T wave to avoid under- as
well as T wave oversensing; at least one out of 3 sensing vectors
needs to have appropriate sensing in a supine and sitting or
standing posture.
CARDIAC RESYNCHRONISATION
THERAPY (CRT)—OF “RESPONDERS”
AND “NON-RESPONDERS”
Cardiac resynchronization therapy has fundamentally
changed the treatment of patients suffering from heart
failure. Impaired left ventricular function often results in
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FIGURE 2 | Antero-posterior chest X-ray after subcutaneous ICD (S-ICD) implantation.
ventricular conduction disease, which secondarily leads
to electrical and mechanical ventricular dyssynchrony
further impairing hemodynamics of the ventricle (19).
Disrupting this vicious is the goal of biventricular pacing
in CRT.
According to current guidelines, a CRT device is indicated
in patients with stable, symptomatic (NYHA II-IVa) systolic
heart failure despite 3 months of optimal medical treatment,
an LVEF ≤ 35% and a QRS duration of ≥ 130ms (1). This
indications results from large randomized trials investigating
the role of cardiac resynchronization in patients with severely
symptomatic heart failure (mostly NYHA III) and a QRS
duration of ≥ 120 ms: The Comparison of Medical Therapy,
Pacing, and Defibrillation in Heart Failure (COMPANION) (20)
and the Cardiac Resynchronisation-Heart Failure (CARE-HF)
(21) trial. Both studies have demonstrated that biventricular
stimulation in this population reduced total mortality up to
36%, which was later confirmed by registry data and meta-
analyses (22–24). Subsequently, the benefit of CRT has been
extended to patients with mild heart failure symptoms (NYHA
II). In the Multicenter Automatic Defibrillator Implantation
Trial with Cardiac Resynchronization Therapy (MADIT-CRT),
heart failure patients with LVEF ≤ 30% and NYHA I-II as
well as a QRS duration of > 130ms were enrolled (25). Total
mortality in the CRT group was 34% lower as compared to
only medically treated patients. This finding is support by data
from the Resynchronization-Defibrillation for Ambulatory Heart
Failure (RAFT) trial, which has shown in patients with LVEF of
≤ 30%, a QRS duration of > 120ms and NYHA II-III that CRT
reduces total mortality by 25% (26).
In spite of these impressive results, a couple of aspects in the
context of CRT need to be discussed:
1. From the MADIT-CRT and RAFT trials, there is insufficient
data to recommend a CRT in patients with NYHA
class I (25, 26).
2. Even though a CRT device reduces mortality in correctly
selected patients, it has no benefit and may cause harm
if implanted in the wrong patients. The EchoCRT trial
demonstrated no benefit and a signal for increased mortality
if a CRT device is implanted in patients with a narrow
QRS complex (despite mechanical ventricular dyssynchrony
as assessed by echocardiography) (27).
3. Guidelines judge a CRT device implantation in patients with a
LBBB with class I indication (IA if QRS width if > 150ms, IB
if QRS duration is 130–149ms), whereas non-LBBB situations
get a class II indication. Patients with LBBB indeed seem
to have a more severe type of LV electrical dyssynchrony
as compared to non-LBBB situation (28, 29) and are likely
to benefit more from cardiac resynchronization. As such,
in the MADIT-CRT trial, a pre-defined subgroup analysis
demonstrated that only patients with LBBB derived a greater
benefit from CRT regarding heart failure event-free survival
(25, 26, 30). This finding is supported by a meta-analysis of
the above mentioned trials showing no benefit of CRT in
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non-LBBB patients (24). One needs to keep in mind that
none of the pivotal trials investigating the role of CRT in
heart failure patients used QRS morphology as an inclusion
criterion (in contrast to QRS duration).
4. Atrial fibrillation (AF) was an exclusion criterion in the vast
majority of CRT trials (except for the RAFT study), even
though AF and heart failure regularly co-exists and patients
with AF together with heart failure exhibit a worse prognosis
(31, 32). Due to fast, irregular atrioventricular conduction,
AF not rarely limits the benefit of a CRT device compared to
sinus rhythm (33). However, if atrial fibrillation conduction
is interrupted by atrioventricular node ablation, the benefit
of a CRT device—at least in non-randomized trials and
meta-analysis—was shown to be similar to patients without
AF (34, 35).
5. On the flip-side one needs to be aware that up to one-
third of patients with a CRT device does not show a
benefit over time (so-called “non-responders”; Figure 3) (37).
However, there is no standard consensus on the definition
of “response” and “non-response”: While some use clinical
parameters (mortality, heart failure hospitalization, NYHA
class) (19, 38), others use echocardiographic measurements
(increase in LVEF, decrease in endsystolic volume) (39) or
a combination. Not rarely, there is a discrepancy between
clinical and echocardiographic responses (40). A typical
example is the response of CRT in patients with ischemic
heart disease. Patients with prior myocardial infarction
are known to demonstrate less of an echocardiographic
response/remodeling to CRT (41, 42). However, the benefit of
CRT in the pivotal trials (CARE-HF and COMPANION) did
not depend on the underlying heart disease (20, 21). On the
contrary, since patients suffering from ischemic heart disease
have a worse prognosis with a higher absolute rate of events,
their absolute risk reductionmay be even higher (43)—and, as
a result, the “number needed to treat” even lower.
Finally, the “response” to CRT is a very relative measure.
Apart from non-responders, as mentioned above, patients
may stabilize their cardiac function and clinical course. We
FIGURE 3 | Possible responses to cardiac resynchronization [Reproduced
with permission from Circulation (36)].
previously coined these individuals “non-progressors” (36). On
a more fundamental level, the lack of visible improvement
in LVEF or clinical status after CRT implantation may lead
physicians to distrust CRT as a valuable way to reduce
morbidity and mortality—leading to the observed lower-than-
expected implementation rates (2). We tend to forget in
these cases that CHF is a chronically progressive, malignant
disease and stabilization of its course—sometimes over years—
often incorrectly termed as “non-response” indeed indicates a
significant benefit of CRT for this vulnerable patient population.
On the other side of the spectrum, some patients exhibit
a huge benefit of CRT and may even normalize their LV
function (so-called “super-responders”; Figure 3) (36). Every
effort has to be undertaken to achieve maximum benefit
from a CRT device. Even though echocardiographic assessment
of ventricular dyssynchrony is not a reliable parameter to
predict outcome to CRT (27, 44), pre-implantation imaging
may become more important to identify optimal position
for the LV lead (45–47). During the implantation, it is
crucial to place the lead—if possible—at the localization
with the longest electrical delay to potentially offer a higher
level of resynchronization (48). Optimal device programming
by experts in device follow-up and troubleshooting post-
implantation and during the further course is furthermore
essential to provide maximum benefit (49). Even though
routinely optimizing device intervals after CRT implantation has
not been shown to be of clinical benefit (50), it may be relevant
in “non-responders,” negative responders and those experiencing
clinical events and complications. In addition, device-based
algorithms to optimize CRT response such as AdaptivCRT
(51, 52) or SyncAV (53) may become more important in the
near future.
In addition to biventricular pacing, other pacing techniques
are under investigation which potentially may further improve
the outcome in patients with heart failure. One such strategy
is His-bundle pacing (HBP); indeed, HBP in the context of
bradycardia indications has been shown to be a safe and
successful option for patients with high burden of chronic
ventricular pacing (54). The role of HBP in heart failure patients
is currently investigated in various trials (HOPE-HF trial, His-
SYNC trial) (55). In how far this will become a standard also
outside expert centers with specific expertise remains to be
proven in large outcome studies.
CONCLUSION
Implantable devices such as ICDs and CRTs are a cornerstone
in the modern treatment of heart failure patients, reducing
morbidity and mortality in this population. Continuing medical
education regarding the pathophysiology, epidemiology,
clinical trial results and novel technologies are of paramount
importance to optimize patient selection and individual
benefit. Ongoing and future studies and technological
advances are aiming to improve patients’ prognosis even
further. Their implementation, however, will be the
task of all stakeholders involved including cardiologists,
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general practitioners and—increasingly importantly—the
patient him/herself. Only by a collaborative effort will
we be able to move the field forward, and to further
develop concepts to improve the prognosis of patients with
heart failure.
AUTHOR CONTRIBUTIONS
All authors listed have made a substantial, direct and
intellectual contribution to the work, and approved it
for publication.
REFERENCES
1. Ponikowski P, Voors AA, Anker SD, BuenoH, Cleland JG, Coats AJ, et al. 2016
ESC Guidelines for the diagnosis and treatment of acute and chronic heart
failure: the task force for the diagnosis and treatment of acute and chronic
heart failure of the European Society of Cardiology (ESC). Developed with
the special contribution of the Heart Failure Association (HFA) of the ESC.
Eur J Heart Failure. (2016) 18:891–975. doi: 10.1002/ejhf.592
2. Dickstein K, Normand C, Auricchio A, Bogale N, Cleland JG, Gitt AK,
et al. CRT Survey II: a European Society of Cardiology survey of cardiac
resynchronisation therapy in 11 088 patients-who is doing what to whom and
how? Eur J Heart Failure. (2018) 20:1039–51. doi: 10.1002/ejhf.1142
3. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, et al.
Meta-analysis of the implantable cardioverter defibrillator secondary
prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics
vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg.
Canadian Implantable Defibrillator Study. Eur Heart J. (2000) 21:2071–8.
doi: 10.1053/euhj.2000.2476
4. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al.
Amiodarone or an implantable cardioverter-defibrillator for congestive heart
failure. N Engl J Med. (2005) 352:225–37. doi: 10.1056/NEJMoa043399
5. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al.
Prophylactic implantation of a defibrillator in patients with myocardial
infarction and reduced ejection fraction. N Engl J Med. (2002) 346:877–83.
doi: 10.1056/NEJMoa013474
6. Kober L, Thune JJ, Nielsen JC, Haarbo J, Videbaek L, Korup E, et al.
Defibrillator implantation in patients with nonischemic systolic heart failure.
N Engl J Med. (2016) 375:1221–30. doi: 10.1056/NEJMoa1608029
7. Haugaa KH, Tilz R, Boveda S, Dobreanu D, Sciaraffia E, Mansourati J, et al.
Implantable cardioverter defibrillator use for primary prevention in ischaemic
and non-ischaemic heart disease-indications in the post-DANISH trial era:
results of the European Heart Rhythm Association survey. Europace. (2017)
19:660–4. doi: 10.1093/europace/eux089
8. Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable defibrillators for
the prevention of mortality in patients with nonischemic cardiomyopathy:
a meta-analysis of randomized controlled trials. JAMA. (2004) 292:2874–9.
doi: 10.1001/jama.292.23.2874
9. Elming MB, Nielsen JC, Haarbo J, Videbaek L, Korup E, Signorovitch J,
et al. Age and outcomes of primary prevention implantable cardioverter-
defibrillators in patients with nonischemic systolic heart failure. Circulation.
(2017) 136:1772–80. doi: 10.1161/CIRCULATIONAHA.117.028829
10. Gorgels AP, Gijsbers C, de Vreede-Swagemakers J, Lousberg A, Wellens
HJ. Out-of-hospital cardiac arrest–the relevance of heart failure. The
Maastricht Circulatory Arrest Registry. Eur Heart J. (2003) 24:1204–9.
doi: 10.1016/S0195-668X(03)00191-X
11. Stecker EC, Vickers C, Waltz J, Socoteanu C, John BT, Mariani R,
et al. Population-based analysis of sudden cardiac death with and without
left ventricular systolic dysfunction: two-year findings from the Oregon
Sudden Unexpected Death Study. J Am Coll Cardiol. (2006) 47:1161–6.
doi: 10.1016/j.jacc.2005.11.045
12. Levy WC, Lee KL, Hellkamp AS, Poole JE, Mozaffarian D, Linker DT,
et al. Maximizing survival benefit with primary prevention implantable
cardioverter-defibrillator therapy in a heart failure population. Circulation.
(2009) 120:835–42. doi: 10.1161/CIRCULATIONAHA.108.816884
13. Moon JC, Reed E, Sheppard MN, Elkington AG, Ho SY, Burke M, et al.
The histologic basis of late gadolinium enhancement cardiovascular magnetic
resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol. (2004)
43:2260–4. doi: 10.1016/j.jacc.2004.03.035
14. Kuruvilla S, Adenaw N, Katwal AB, Lipinski MJ, Kramer CM, Salerno M.
Late gadolinium enhancement on cardiac magnetic resonance predicts
adverse cardiovascular outcomes in nonischemic cardiomyopathy: a
systematic review and meta-analysis. Circ Cardiovasc Imag. (2014) 7:250–8.
doi: 10.1161/CIRCIMAGING.113.001144
15. Halliday BP, Gulati A, Ali A, Guha K, Newsome S, Arzanauskaite M,
et al. Association between midwall late gadolinium enhancement and
sudden cardiac death in patients with dilated cardiomyopathy and mild and
moderate left ventricular systolic dysfunction. Circulation. (2017) 135:2106–
15. doi: 10.1161/CIRCULATIONAHA.116.026910
16. Sasaki T, Miller CF, Hansford R, Zipunnikov V, Zviman MM, Marine
JE, et al. Impact of nonischemic scar features on local ventricular
electrograms and scar-related ventricular tachycardia circuits in patients with
nonischemic cardiomyopathy. Circ Arrhythmia Electrophysiol. (2013) 6:1139–
47. doi: 10.1161/CIRCEP.113.000159
17. Brouwer TF, Yilmaz D, Lindeboom R, Buiten MS, Olde Nordkamp LR, Schalij
MJ, et al. Long-term clinical outcomes of subcutaneous versus transvenous
implantable defibrillator therapy. J Am Coll Cardiol. (2016) 68:2047–55.
doi: 10.1016/j.jacc.2016.08.044
18. Priori SG, Blomstrom-Lundqvist C. 2015 European Society of Cardiology
Guidelines for the management of patients with ventricular arrhythmias and
the prevention of sudden cardiac death summarized by co-chairs. Eur Heart J.
(2015) 36:2757–9. doi: 10.1093/eurheartj/ehv316
19. Young JB, Abraham WT, Smith AL, Leon AR, Lieberman R, Wilkoff B,
et al. Combined cardiac resynchronization and implantable cardioversion
defibrillation in advanced chronic heart failure: the MIRACLE ICD trial.
JAMA. (2003) 289:2685–94. doi: 10.1001/jama.289.20.2685
20. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T,
et al. Cardiac-resynchronization therapy with or without an implantable
defibrillator in advanced chronic heart failure.N Engl J Med. (2004) 350:2140–
50. doi: 10.1056/NEJMoa032423
21. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L,
et al. The effect of cardiac resynchronization on morbidity and mortality in
heart failure. N Engl J Med. (2005) 352:1539–49. doi: 10.1056/NEJMoa050496
22. Bilchick KC, Kamath S, DiMarco JP, Stukenborg GJ. Bundle-branch
block morphology and other predictors of outcome after cardiac
resynchronization therapy in Medicare patients. Circulation. (2010)
122:2022–30. doi: 10.1161/CIRCULATIONAHA.110.956011
23. Gold MR, Thebault C, Linde C, Abraham WT, Gerritse B, Ghio S, et al.
Effect of QRS duration and morphology on cardiac resynchronization
therapy outcomes in mild heart failure: results from the resynchronization
reverses remodeling in systolic left ventricular dysfunction (REVERSE)
study. Circulation. (2012) 126:822–9. doi: 10.1161/CIRCULATIONAHA.112.
097709
24. Cunnington C, Kwok CS, Satchithananda DK, Patwala A, Khan MA, Zaidi
A, et al. Cardiac resynchronisation therapy is not associated with a reduction
in mortality or heart failure hospitalisation in patients with non-left bundle
branch block QRSmorphology: meta-analysis of randomised controlled trials.
Heart. (2015) 101:1456–62. doi: 10.1136/heartjnl-2014-306811
25. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, et al.
Cardiac-resynchronization therapy for the prevention of heart-failure events.
N Engl J Med. (2009) 361:1329–38. doi: 10.1056/NEJMoa0906431
26. Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, et al.
Cardiac-resynchronization therapy for mild-to-moderate heart failure.N Engl
J Med. (2010) 363:2385–95. doi: 10.1056/NEJMoa1009540
27. Ruschitzka F, AbrahamWT, Singh JP, Bax JJ, Borer JS, Brugada J, et al. Cardiac-
resynchronization therapy in heart failure with a narrowQRS complex.NEngl
J Med. (2013) 369:1395–405. doi: 10.1056/NEJMoa1306687
Frontiers in Cardiovascular Medicine | www.frontiersin.org 6 August 2019 | Volume 6 | Article 111
Breitenstein and Steffel Devices in Heart Failure
28. Haghjoo M, Bagherzadeh A, Farahani MM, Haghighi ZO, Sadr-Ameli MA.
Significance of QRSmorphology in determining the prevalence of mechanical
dyssynchrony in heart failure patients eligible for cardiac resynchronization:
particular focus on patients with right bundle branch block with and
without coexistent left-sided conduction defects. Europace. (2008) 10:566–71.
doi: 10.1093/europace/eun081
29. Yu CM, Fung JW, Chan CK, Chan YS, Zhang Q, Lin H, et al.
Comparison of efficacy of reverse remodeling and clinical improvement for
relatively narrow and wide QRS complexes after cardiac resynchronization
therapy for heart failure. J Cardiovasc Electrophysiol. (2004) 15:1058–65.
doi: 10.1046/j.1540-8167.2004.03648.x
30. Zareba W, Klein H, Cygankiewicz I, Hall WJ, McNitt S, Brown M, et al.
Effectiveness of cardiac resynchronization therapy by qrs morphology
in the multicenter automatic defibrillator implantation trial-cardiac
resynchronization therapy (MADIT-CRT). Circulation. (2011) 123:1061–72.
doi: 10.1161/CIRCULATIONAHA.110.960898
31. Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL, McMurray
JJ, et al. Atrial fibrillation and risk of clinical events in chronic heart
failure with and without left ventricular systolic dysfunction: results from
the Candesartan in Heart Failure—Assessment of Reduction in Mortality
and morbidity (CHARM) program. J Am Coll Cardiol. (2006) 47:1997–2004.
doi: 10.1016/j.jacc.2006.01.060
32. Trulock KM, Narayan SM, Piccini JP. Rhythm control in heart failure patients
with atrial fibrillation: contemporary challenges including the role of ablation.
J Am Coll Cardiol. (2014) 64:710–21. doi: 10.1016/j.jacc.2014.06.1169
33. Wilton SB, Leung AA, Ghali WA, Faris P, Exner DV. Outcomes of cardiac
resynchronization therapy in patients with versus those without atrial
fibrillation: a systematic review and meta-analysis. Heart Rhythm. (2011)
8:1088–94. doi: 10.1016/j.hrthm.2011.02.014
34. Gasparini M, Auricchio A, Metra M, Regoli F, Fantoni C, Lamp B,
et al. Long-term survival in patients undergoing cardiac resynchronization
therapy: the importance of performing atrio-ventricular junction ablation in
patients with permanent atrial fibrillation. Eur Heart J. (2008) 29:1644–52.
doi: 10.1093/eurheartj/ehn133
35. Ganesan AN, Brooks AG, Roberts-Thomson KC, Lau DH, Kalman JM,
Sanders P. Role of AV nodal ablation in cardiac resynchronization in patients
with coexistent atrial fibrillation and heart failure a systematic review. J Am
Coll Cardiol. (2012) 59:719–26. doi: 10.1016/j.jacc.2011.10.891
36. Steffel J, Ruschitzka F. Superresponse to cardiac resynchronization therapy.
Circulation. (2014) 130:87–90. doi: 10.1161/CIRCULATIONAHA.113.006124
37. Versteeg H, Schiffer AA, Widdershoven JW, Meine MM, Doevendans
PA, Pedersen SS. Response to cardiac resynchronization therapy: is it
time to expand the criteria? Pacing Clin Electrophysiol. (2009) 32:1247–56.
doi: 10.1111/j.1540-8159.2009.02505.x
38. Packer M. Proposal for a new clinical end point to evaluate the efficacy of
drugs and devices in the treatment of chronic heart failure. J Cardiac Failure.
(2001) 7:176–82. doi: 10.1054/jcaf.2001.25652
39. Pitzalis MV, Iacoviello M, Romito R, Massari F, Rizzon B, Luzzi G,
et al. Cardiac resynchronization therapy tailored by echocardiographic
evaluation of ventricular asynchrony. J Am Coll Cardiol. (2002) 40:1615–22.
doi: 10.1016/S0735-1097(02)02337-9
40. Bleeker GB, Bax JJ, Fung JW, van der Wall EE, Zhang Q, Schalij MJ,
et al. Clinical versus echocardiographic parameters to assess response
to cardiac resynchronization therapy. Am J Cardiol. (2006) 97:260–3.
doi: 10.1016/j.amjcard.2005.08.030
41. Adelstein EC, Saba S. Scar burden by myocardial perfusion imaging
predicts echocardiographic response to cardiac resynchronization
therapy in ischemic cardiomyopathy. Am Heart J. (2007) 153:105–12.
doi: 10.1016/j.ahj.2006.10.015
42. Gasparini M, Mantica M, Galimberti P, Genovese L, Pini D, Faletra
F, et al. Is the outcome of cardiac resynchronization therapy related
to the underlying etiology? Pacing Clin Electrophysiol. (2003) 26:175–80.
doi: 10.1046/j.1460-9592.2003.00011.x
43. Wikstrom G, Blomstrom-Lundqvist C, Andren B, Lonnerholm S, Blomstrom
P, Freemantle N, et al. The effects of aetiology on outcome in patients treated
with cardiac resynchronization therapy in the CARE-HF trial. Eur Heart J.
(2009) 30:782–8. doi: 10.1093/eurheartj/ehn577
44. Chung ES, Leon AR, Tavazzi L, Sun JP, Nihoyannopoulos P, Merlino J, et al.
Results of the predictors of response to CRT (PROSPECT) trial. Circulation.
(2008) 117:2608–16. doi: 10.1161/CIRCULATIONAHA.107.743120
45. Khan FZ, Virdee MS, Palmer CR, Pugh PJ, O’Halloran D, Elsik M, et al.
Targeted left ventricular lead placement to guide cardiac resynchronization
therapy: the TARGET study: a randomized, controlled trial. J Am Coll Cardiol.
(2012) 59:1509–18. doi: 10.1016/j.jacc.2011.12.030
46. Saba S, Marek J, Schwartzman D, Jain S, Adelstein E, White P, et al.
Echocardiography-guided left ventricular lead placement for cardiac
resynchronization therapy: results of the Speckle Tracking Assisted
Resynchronization Therapy for Electrode Region trial. Circ Heart Failure.
(2013) 6:427–34. doi: 10.1161/CIRCHEARTFAILURE.112.000078
47. Leyva F, Foley PW, Chalil S, Ratib K, Smith RE, Prinzen F, et al.
Cardiac resynchronization therapy guided by late gadolinium-enhancement
cardiovascular magnetic resonance. J Cardiovasc Magn Resonance. (2011)
13:29. doi: 10.1186/1532-429X-13-29
48. Roubicek T, Wichterle D, Kucera P, Nedbal P, Kupec J, Sedlakova J, et al. Left
ventricular lead electrical delay is a predictor of mortality in patients with
cardiac resynchronization therapy. Circ Arrhythmia Electrophysiol. (2015)
8:1113–21. doi: 10.1161/CIRCEP.115.003004
49. Steffel J, Rempel H, Breitenstein A, Schmidt S, Namdar M, Krasniqi N, et al.
Comprehensive cardiac resynchronization therapy optimization in the real
world. Cardiol J. (2014) 21:316–24. doi: 10.5603/CJ.a2013.0123
50. Ellenbogen KA, Gold MR, Meyer TE, Fernndez Lozano I, Mittal S,
Waggoner AD, et al. Primary results from the SmartDelay determined AV
optimization: a comparison to other AV delay methods used in cardiac
resynchronization therapy (SMART-AV) trial: a randomized trial comparing
empirical, echocardiography-guided, and algorithmic atrioventricular delay
programming in cardiac resynchronization therapy. Circulation. (2010)
122:2660–8. doi: 10.1161/CIRCULATIONAHA.110.992552
51. Martin DO, Lemke B, Birnie D, Krum H, Lee KL, Aonuma K,
et al. Investigation of a novel algorithm for synchronized left-ventricular
pacing and ambulatory optimization of cardiac resynchronization therapy:
results of the adaptive CRT trial. Heart Rhythm. (2012) 9:1807–14.
doi: 10.1016/j.hrthm.2012.07.009
52. Singh JP, Abraham WT, Chung ES, Rogers T, Sambelashvili A, Coles JA Jr,
et al. Clinical response with adaptive CRT algorithm compared with CRT with
echocardiography-optimized atrioventricular delay: a retrospective analysis of
multicentre trials. Europace. (2013) 15:1622–8. doi: 10.1093/europace/eut107
53. Varma N, O’Donnell D, Bassiouny M, Ritter P, Pappone C, Mangual J, et al.
Programming cardiac resynchronization therapy for electrical synchrony:
reaching beyond left bundle branch block and left ventricular activation delay.
J Am Heart Assoc. (2018) 7:e007489. doi: 10.1161/JAHA.117.007489
54. Abdelrahman M, Subzposh FA, Beer D, Durr B, Naperkowski A, Sun H, et al.
Clinical outcomes of his bundle pacing compared to right ventricular pacing.
J Am Coll Cardiol. (2018) 71:2319–30. doi: 10.1016/j.jacc.2018.02.048
55. Lewis AJM, Foley P, Whinnett Z, Keene D, Chandrasekaran B. His bundle
pacing: a new strategy for physiological ventricular activation. J Am Heart
Assoc. (2019) 8:e010972. doi: 10.1161/JAHA.118.010972
Conflict of Interest Statement: AB has received consultant and/or speaker
fees from Abbott, Bayer, Biosense Webster, Biotronik, Boston Scientific, Bristol-
Myers Squibb, Daiichi Sankyo, Medtronic, Novartis, and Spectranetics/Philipps.
JS has received consultant and/or speaker fees from Abbott, Amgen, Astra-
Zeneca, Atricure, Bayer, Biosense Webster, Biotronik, Boehringer-Ingelheim,
Boston Scientific, Bristol-Myers Squibb, Daiichi Sankyo, Medscape, Medtronic,
Merck/MSD, Novartis, Pfizer, Sanofi-Aventis, WebMD, and Zoll. He reports
ownership of CorXL. JS has received grant support through his institution from
Abbott, Bayer Healthcare, Biosense Webster, Biotronik, Boston Scientific, Daiichi
Sankyo, and Medtronic.
Copyright © 2019 Breitenstein and Steffel. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) and the copyright owner(s) are credited and that the original publication
in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Cardiovascular Medicine | www.frontiersin.org 7 August 2019 | Volume 6 | Article 111
